Saol Therapeutics is a clinical-stage pharmaceutical company that focuses on developing innovative treatments for central nervous system (CNS) disorders, including pain, spasticity, and orphan diseases. The company is advancing several proprietary technologies, notably SL-1002, a novel neurolytic agent currently undergoing Phase 2 trials for pain related to osteoarthritis and limb spasticity. This agent is designed to provide a non-opioid alternative for managing pain, addressing a significant unmet need in the treatment landscape. Saol's approach emphasizes practical innovation, building on established scientific knowledge to enhance the standard of care for patients suffering from these conditions.

In addition to SL-1002, Saol is developing SL-1009, which targets Pyruvate Dehydrogenase Complex Deficiency (PDCD), a rare mitochondrial disorder. This treatment is positioned to be the first FDA-approved therapy for this condition, utilizing individualized genetically driven dosing to optimize patient outcomes. Saol's commitment to addressing unmet medical needs is further reflected in its strategic partnerships with clinicians, scientists, and biopharmaceutical companies, aiming to foster collaboration that enhances the development and delivery of its innovative therapies.

United States

Saol Therapeutics (pronounced "Sail") is a privately held, clinical-stage, pharmaceutical company with operations in Roswell, GA, Dublin, Ireland and Hamilton, Bermuda.  The company is focused on development activity in CNS disorders such as pain management and spasticity and orphan diseases.  Saol is committed to providing and advancing therapeutic options for patients and the physicians treating these populations and currently has two Phase 2 trials and one Phase 3 trail underway in the United States.  

Saol Therapeutics

Company Details